Normocapnia Versus Mild Hypercapnia During Lung Protective Ventilation in Acute Respiratory Distress Syndrome: A Target Trial Emulation
In brief
Matching carbon dioxide to normal levels did not lower ARDS mortality
In a target trial emulation of 584 patients with acute respiratory distress syndrome, 90-day in-hospital mortality was identical at 28.8% whether ventilation aimed for normal carbon dioxide levels or allowed mild hypercapnia. The normal-carbon-dioxide group had a higher respiratory rate, but no survival advantage; because this was an emulation rather than a randomized trial, residual bias remains a concern.
- Journal
- Critical care medicine (Q1)
- Published
- 11 November 2026
- Study design
- Retrospective cohort
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Vassilis G Giannakoulis, Eleni Papoutsi, Konstantinos Gkirgkiris, Zacharias Diakonikolaou, Evgenia Kalamara, Aikaterini Katsogianni, et al.
- PMID
- 43012617
- DOI
- 10.1097/CCM.0000000000007434
Why clinicians should know about it
- Picked for Critical Care and Intensive Care Medicine (paper of the day, 14 November 2026): ARDS ventilation strategy and mortality under normocapnia versus hypercapnia
Abstract
OBJECTIVES: This trial emulation aimed to answer the question: Among patients with acute respiratory distress syndrome (ARDS) who receive lung protective ventilation with low tidal volume, is normocapnia through an increase in respiratory rate associated with lower mortality than mild hypercapnia? DESIGN: Target trial emulation. SETTING: Hospitals of the ARDS Network and Prevention and Early Treatment of Acute Lung Injury (PETAL) Network. PATIENTS: Patients with ARDS enrolled in seven ARDS Network and PETAL Network randomized controlled trials. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: A target trial was emulated, assigning participants in a 1:1 ratio to normocapnia (target Paco2 35-45 mm Hg) or mild hypercapnia (target Paco2 50-55 mm Hg) for 4 days following the initiation of lung protective ventilation. The primary outcome was 90-day in-hospital mortality. Of 5367 potentially eligible subjects, 292 patients were assigned to normocapnia and 292 to mild hypercapnia. Separation in Paco2 values was preserved over the 4-day period of emulated intervention. Both groups had median pH greater than or equal to 7.33. Bicarbonate levels, driving pressure, tidal volume, and dead-space fraction did not differ clinically significantly between groups, while median respiratory rate was 33.0 breaths/min in the normocapnia vs. 28.0 breaths/min in the mild hypercapnia group (p < 0.001). Death within 90 days occurred in 84 of 292 patients (28.8%) in the normocapnia group and in 84 of 292 patients (28.8%) in the mild hypercapnia group (log-rank p = 0.842). This result persisted in subgroups such as older (≥ 65 yr) and obese (body mass index ≥ 30 kg/m2) patients. CONCLUSIONS: Among patients with ARDS who received lung protective ventilation, normocapnia through an increase in respiratory rate was not associated with lower mortality than mild hypercapnia. As this finding is derived from a trial emulation, it should be interpreted cautiously given the potential for significant residual bias.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.